205 related articles for article (PubMed ID: 2162156)
1. Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion.
Jarzabek-Chorzelska M; Blaszczyk M; Kolacinska-Strasz Z; Chorzelski T; Jabłońska S; Maul GG
Arch Dermatol Res; 1990; 282(2):76-83. PubMed ID: 2162156
[TBL] [Abstract][Full Text] [Related]
2. Are ACA and Scl 70 antibodies mutually exclusive?
Jarzabek-Chorzelska M; Błaszczyk M; Kołacińska-Strasz Z; Jabłonska S; Chorzelski T; Maul GG
Br J Dermatol; 1990 Feb; 122(2):201-8. PubMed ID: 2107867
[TBL] [Abstract][Full Text] [Related]
3. Immunological markers of the subsets of systemic scleroderma and its overlap.
Jabłońska S; Błaszczyk M; Jarzabek-Chorzelska M; Chorzelski T; Kołacińska-Strasz Z
Arch Immunol Ther Exp (Warsz); 1991; 39(4):381-90. PubMed ID: 1821614
[TBL] [Abstract][Full Text] [Related]
4. Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis.
Tamby MC; Servettaz A; Guilpain P; Tamas N; Berezné A; Batteux F; Reinbolt J; Guillevin L; Weill B; Mouthon L
Clin Immunol; 2007 Apr; 123(1):82-8. PubMed ID: 17258939
[TBL] [Abstract][Full Text] [Related]
5. Redefining the Scl-70 indirect immunofluorescence pattern: autoantibodies to DNA topoisomerase I yield a specific compound immunofluorescence pattern.
Dellavance A; Gallindo C; Soares MG; da Silva NP; Mortara RA; Andrade LE
Rheumatology (Oxford); 2009 Jun; 48(6):632-7. PubMed ID: 19395540
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study.
Weiner ES; Hildebrandt S; Senécal JL; Daniels L; Noell S; Joyal F; Roussin A; Earnshaw W; Rothfield NF
Arthritis Rheum; 1991 Jan; 34(1):68-77. PubMed ID: 1845841
[TBL] [Abstract][Full Text] [Related]
7. Scl 70 antibody--a specific marker of systemic sclerosis.
Jarzabek-Chorzelska M; Blaszczyk M; Jablonska S; Chorzelski T; Kumar V; Beutner EH
Br J Dermatol; 1986 Oct; 115(4):393-401. PubMed ID: 3535866
[TBL] [Abstract][Full Text] [Related]
8. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients.
Weiner ES; Earnshaw WC; Senécal JL; Bordwell B; Johnson P; Rothfield NF
Arthritis Rheum; 1988 Mar; 31(3):378-85. PubMed ID: 2833902
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides.
Seelig HP; Schröter H; Ehrfeld H; Renz M
J Immunol Methods; 1993 Oct; 165(2):241-52. PubMed ID: 8228274
[TBL] [Abstract][Full Text] [Related]
10. Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins.
Cram DS; Fisicaro N; McNeilage LJ; Coppel RL; Harrison LC
J Immunol; 1993 Dec; 151(12):6872-81. PubMed ID: 7505017
[TBL] [Abstract][Full Text] [Related]
11. Autoantibodies in systemic sclerosis.
Vázquez-Abad D; Rothfield NF
Int Rev Immunol; 1995; 12(2-4):145-57. PubMed ID: 7650418
[TBL] [Abstract][Full Text] [Related]
12. [Nuclear antibodies as serologic markers in progressive systemic scleroderma].
Lakomek HJ; Guldner HH; Bautz FA; Goerz G; Kind P; Mensing H; Krüskemper HL
Hautarzt; 1987 Feb; 38(2):63-9. PubMed ID: 3106261
[TBL] [Abstract][Full Text] [Related]
13. Scl 70 autoantibodies from scleroderma patients recognize a 95 kDa protein identified as DNA topoisomerase I.
Guldner HH; Szostecki C; Vosberg HP; Lakomek HJ; Penner E; Bautz FA
Chromosoma; 1986; 94(2):132-8. PubMed ID: 2428564
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Dick T; Mierau R; Bartz-Bazzanella P; Alavi M; Stoyanova-Scholz M; Kindler J; Genth E
Ann Rheum Dis; 2002 Feb; 61(2):121-7. PubMed ID: 11796397
[TBL] [Abstract][Full Text] [Related]
15. A case of systemic sclerosis with anticentromere, antitopoisomerase I, and anti-U1RNP antibodies.
Sato S; Ihn H; Soma Y; Shimozuma M; Shishiba T; Takehara K
J Rheumatol; 1993 Nov; 20(11):1961-3. PubMed ID: 8308786
[TBL] [Abstract][Full Text] [Related]
16. Serological markers in progressive systemic sclerosis: clinical correlations.
Catoggio LJ; Bernstein RM; Black CM; Hughes GR; Maddison PJ
Ann Rheum Dis; 1983 Feb; 42(1):23-7. PubMed ID: 6402991
[TBL] [Abstract][Full Text] [Related]
17. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies.
Cassani F; Tosti A; Bianchi FB; Fusconi M; Selleri L; Baffoni L; Veronesi S; Volta U; Lenzi M; Pisi E
Clin Exp Rheumatol; 1987; 5(1):23-8. PubMed ID: 3109797
[TBL] [Abstract][Full Text] [Related]
18. Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Hénault J; Tremblay M; Clément I; Raymond Y; Senécal JL
Arthritis Rheum; 2004 Oct; 50(10):3265-74. PubMed ID: 15476238
[TBL] [Abstract][Full Text] [Related]
19. Marker antibodies in scleroderma and polymyositis: clinical associations.
de Rooij DJ; Van de Putte LB; Habets WJ; Van Venrooij WJ
Clin Rheumatol; 1989 Jun; 8(2):231-7. PubMed ID: 2547546
[TBL] [Abstract][Full Text] [Related]
20. Scleroderma: DR antigens, autoantibodies and clinical manifestations.
Alarcón GS; McCarty GA; Lanyon P; Phillips RM; Acton RT; Barger BO
Clin Exp Rheumatol; 1987; 5(4):317-21. PubMed ID: 3326691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
